Drosophila modifier screens to identify novel neuropsychiatric drugs including aminergic agents for the possible treatment of Parkinson’s disease and depression
Authors:
Open Access
- 11 December 2012
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 19 (2) , 235-242
Abstract
Small molecules that increase the presynaptic function of aminergic cells may provide neuroprotection in Parkinson’s disease (PD) as well as treatments for attention deficit hyperactivity disorder (ADHD) and depression. Model genetic organisms such as Drosophila melanogaster may enhance the detection of new drugs via modifier or ‘enhancer/suppressor’ screens, but this technique has not been applied to processes relevant to psychiatry. To identify new aminergic drugs in vivo, we used a mutation in the Drosophila vesicular monoamine transporter (dVMAT) as a sensitized genetic background and performed a suppressor screen. We fed dVMAT mutant larvae ∼ 1000 known drugs and quantitated rescue (suppression) of an amine-dependent locomotor deficit in the larva. To determine which drugs might specifically potentiate neurotransmitter release, we performed an additional secondary screen for drugs that require presynaptic amine storage to rescue larval locomotion. Using additional larval locomotion and adult fertility assays, we validated that at least one compound previously used clinically as an antineoplastic agent potentiates the presynaptic function of aminergic circuits. We suggest that structurally similar agents might be used to development treatments for PD, depression and ADHD, and that modifier screens in Drosophila provide a new strategy to screen for neuropsychiatric drugs. More generally, our findings demonstrate the power of physiologically based screens for identifying bioactive agents for select neurotransmitter systems.Keywords
This publication has 38 references indexed in Scilit:
- Adenosine A2A receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillationMolecular Psychiatry, 2012
- The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neuronsNeurobiology of Disease, 2010
- Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra NeuronsNeuron, 2009
- The Octopamine Receptor OAMB Mediates Ovulation via Ca2+/Calmodulin-Dependent Protein Kinase II in the Drosophila Oviduct EpitheliumPLOS ONE, 2009
- Drosophila Vesicular Monoamine Transporter Mutants Can Adapt to Reduced or Eliminated Vesicular Stores of Dopamine and SerotoninGenetics, 2009
- Vmat2Heterozygous Mutant Mice Display a Depressive-Like PhenotypeJournal of Neuroscience, 2007
- ADrosophilaModel of Mutant Human Parkin-Induced Toxicity Demonstrates Selective Loss of Dopaminergic Neurons and Dependence on Cellular DopamineJournal of Neuroscience, 2007
- 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside-induced AMP-activated Protein Kinase Phosphorylation Inhibits Basal and Insulin-stimulated Glucose Uptake, Lipid Synthesis, and Fatty Acid Oxidation in Isolated Rat AdipocytesJournal of Biological Chemistry, 2006
- Chronic cocaine exposure in Drosophila: Life, cell death and oogenesisDevelopmental Biology, 2006
- Overexpression of the Drosophila vesicular monoamine transporter increases motor activity and courtship but decreases the behavioral response to cocaineMolecular Psychiatry, 2005